GPRC5D CAR T / Sana Biotech - LARVOL DELTA

Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients (ASH 2023) - "Studies to further define the efficacy of HIP-modified GPRC5D CAR T cells are ongoing. Moving forward, further interrogating GPRC5D CAR activity against multiple myeloma tumor cells with varying levels of target antigen expression will be critical to understanding the benefit of deploying GPRC5D CAR T cells within the multiple myeloma clinical landscape."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • B2M • CD47 • CIITA

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting (GlobeNewswire) - "Sana Biotechnology, Inc...today announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology were presented at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA...The results demonstrated that CD22 HIP CAR T cells evaded adaptive immune cell recognition and cytolysis through B2M and CIITA gene disruption and innate immune cell recognition through the overexpression of CD47...Sana submitted the investigational new drug (IND) application and intends to begin human testing of SC262 in early 2024...The data showed that candidate GPRC5D CARs elicited in vitro cytotoxicity and effector cytokine production that is comparable to clinically validated benchmark control CARs....these GPRC5D CAR T cells controlled multiple myeloma tumor cells both in vitro and in vivo, demonstrating efficacy that is on par with clinical benchmark GPRC5D CAR T cells."

New trial • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting (GlobeNewswire) - "Sana Biotechnology, Inc...today announced that five abstracts will have poster presentations at the 65^th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology